Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LAP3 | P28838 | 3/20 | 0.46 |
| ▸ | ANPEP | P15144 | 3/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | ACP3 | P15309 | 2/20 | 0.44 |
| ▸ | TSHR | P16473 | 3/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | CFTR | P13569 | 1/20 | 0.43 |
| ▸ | ERAP1 | Q9NZ08 | 2/20 | 0.43 |
| ▸ | CA2 | P00918 | 1/20 | 0.43 |
| ▸ | CA4 | P22748 | 1/20 | 0.43 |
| ▸ | CA5A | P35218 | 1/20 | 0.43 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.43 |
| ▸ | FDPS | P14324 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1655196 | 0.96 | LAP3 (0.46) | LAP3ANPEPHPGDACP3TSHR | |
| SCHEMBL10383331 | 0.94 | LAP3 (0.44) | LAP3ANPEPHPGDACP3TSHR | |
| SCHEMBL7192594 | 0.87 | HTT (0.50) | LAP3ANPEPHPGDTSHRALDH1A1 | |
| SCHEMBL6833041 | 0.87 | LAP3 (0.40) | LAP3ANPEPHPGDNPC1RAB9A | |
| SCHEMBL9505404 | 0.84 | ALOX15 (0.41) | LAP3ANPEPHPGDACP3TSHR | |
| SCHEMBL9715390 | 0.82 | LAP3 (0.44) | LAP3ANPEPHPGDACP3TSHR | |
| SCHEMBL24673276 | 0.81 | CNR2 (0.43) | HPGDTSHRALDH1A1MEN1KMT2A | |
| SCHEMBL9505356 | 0.81 | ANPEP (0.40) | LAP3ANPEPACP3ALDH1A1ERAP1 | |
| SCHEMBL12227404 | 0.80 | MEN1 (0.50) | LAP3ANPEPHPGDTSHRALDH1A1 | |
| SCHEMBL9315590 | 0.79 | TSHR (0.53) | LAP3ANPEPHPGDTSHRALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7750180-B2 | Process for the preparation of N-phosphonomethylglycine and derivatives thereof | MONSANTO TECHNOLOGY LLC (US) | 2010-07-06 | — | — | US | disclosed |
| EP-1664068-A2 | PROCESS FOR THE PREPARATION OF N-PHOSPHONO-METHYLGLYCINE AND DERIVATIVES THEREOF | Monsanto Technology, LLC (US) | 2006-06-07 | — | — | EP | disclosed |
| US-20050054871-A1 | Process for the preparation of N-phosphonomethylglycine and derivatives thereof | MONSANTO TECHNOLOGY LLC | 2005-03-10 | — | — | US | disclosed |
| WO-2005019230-A2 | PROCESS FOR THE PREPARATION OF N-PHOSPHONO-METHYLGLYCINE AND DERIVATIVES THEREOF | MONSANTO TECHNOLOGY LLC (US) | 2005-03-03 | — | — | WO | disclosed |
| EP-0078766-B1 | PROCESS FOR PREPARING AMINOMETHYLPHOSPHONIC ACID | CIBA-GEIGY AG (CH) | 1985-04-17 | — | — | EP | disclosed |
| EP-0078766-A1 | Process for preparing aminomethylphosphonic acid | CIBA-GEIGY AG (CH) | 1983-05-11 | — | — | EP | disclosed |
| US-4368162-A | Process for producing aminomethylphosphonic acid | CIBA-GEIGY CORPORATION (US) | 1983-01-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050054871-A1 | Process for the preparation of N-phosphonomethylglycine and derivatives thereof | PHOSPHO1, GNE, MPHOSPH6 | LAP3 667/4885ANPEP 85/4885HPGD 648/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.